Lion's main man

After two years spent building Acerta Pharma B.V., Quogue Capital's Wayne Rothbaum is picking up where he left off in 2013 - pushing Lion Biotechnologies Inc. (NASDAQ:LBIO) toward pivotal testing with what he thinks is the industry's most active and durable single-agent melanoma therapy.

Lion was Quogue's last disclosed investment before Rothbaum put investing on hold to become Acerta's executive chairman. In December, AstraZeneca plc (LSE:AZN; NYSE:AZN) paid $4 billion for a 55% stake and gained acalabrutinib, a Bruton's tyrosine kinase (Btk) inhibitor for multiple cancers...